Medical Condition News

RSS

Nighttime coughing could be due to air pollution levels, research suggests

Has your partner ever woken you up at night with their coughing? Has your coughing ever woken them up? New research suggests it could be due to air pollution levels in your area, even if those levels are low.

15 Sep 2026

Genetic variant accelerates Huntington’s disease onset by over a decade

A new study has revealed why some people with Huntington disease develop symptoms 10 to 12 years earlier and experience a more aggressive form of the disease.

15 Sep 2026

New structural insights could improve treatments for neurological disorders

Metabotropic glutamate receptors, which are important but difficult drug targets, interact in surprisingly varied ways with their principal regulatory proteins, according to two new studies led by Weill Cornell Medicine investigators.

15 Sep 2026

Silica and dust mites combine to worsen asthma inflammation

Inflammation associated with asthma and other allergic airway diseases can be significantly worsened by exposure to both house dust mite allergens and crystalline silica, according to a new study published in the journal Allergy.

15 Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Study links processed foods to targeted domain-specific cognitive decline

An unhealthy Western-style diet was associated with a faster cognitive decline in people with a genetic risk of Alzheimer's disease, according to new research led by Murdoch University and Alzheimer's Research Australia.

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Air pollution linked to higher risks of glaucoma and cataract

People who live in areas with higher levels of air pollution are more likely to develop glaucoma and cataract, according to a large study presented today (Monday) at the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).

15 Sep 2026

Smartphone imaging accurately supports remote cataract referral decisions

Researchers have found a high level of agreement between cataract referral decisions based on smartphone images reviewed remotely and those made by ophthalmologists examining patients in person at rural eye camps.

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Medical Condition News

Nighttime coughing could be due to air pollution levels, research suggests

Genetic variant accelerates Huntington’s disease onset by over a decade

New structural insights could improve treatments for neurological disorders

Silica and dust mites combine to worsen asthma inflammation

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Study links processed foods to targeted domain-specific cognitive decline

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

Air pollution linked to higher risks of glaucoma and cataract

Smartphone imaging accurately supports remote cataract referral decisions

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News